2015 Leads Physicians 
World of DTC Marketing
JUNE 27, 2021
Yet the media has led with “diabetes drug leads to major weight loss” Will doctors inform patients? But, will physicians tell patients that results depend on lifestyle intervention and a low-calorie diet? The drug carries a potential risk for a type of thyroid tumor and has a boxed warning.
European Pharmaceutical Review
JANUARY 24, 2023
The three new European hires are: Maria Lehretz, Medical Director, Velocity Leipzig, Germany Maria has nearly a decade of experience as a clinical research physician, and has worked on approximately 70 clinical trials. She was medical lead at SIBAmed GmbH for four years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
APRIL 24, 2023
CVS then began affiliating with health systems across the country (like Cleveland Clinic ) for physician oversight of MinuteClinic’s staffed midlevel providers, just as Walgreens was rising as a formidable competitor in the convenient care space through its own walk-in clinics that it launched in fall 2006. Key acquisitions by U.S.
Medgadget
MARCH 2, 2023
This leads to substantial damage to healthy tissues and too often results in poor outcomes. Some years later, in 2015, Alpha TAU was founded by Uzi Sofer, the company’s CEO, to give the technology another opportunity to prove itself. which are currently recruiting patients.
Evolve Your Success
OCTOBER 18, 2022
The last thing I would add is right around 2015, Andrew Chen at Uber, who’s the VP of Growth there, wrote this article called The Growth Hacker Is The New VP Marketing. The idea of trying to sell and influence hospitals and physicians using social media was a joke, but the data said otherwise. You have to coach your physician.
Pharmaceutical Technology
MARCH 24, 2023
Until 2010, no regulatory approval pathway for biosimilars existed in the US and the first biosimilar was only approved in the US in 2015. Many experts have concerns that only a few Humira biosimilars will have access to the US market, while the rest will not be listed, thereby leading to lower savings than expected.
pharmaphorum
JULY 4, 2022
The major goal is to bring affected persons, relatives of affected persons, and physicians, together with experts for Rare Diseases, healthcare providers, and special patient organisations, which are very important in the context of Rare Diseases,” he explains. About the panel.
Expert insights. Personalized for you.
194 
Let's personalize your content